Neoadjuvant zoledronic acid for HER2-positive breast cancer: the Zo-NAnTax trial
Background: Preclinical evidence suggests that zoledronic acid (ZOL) works synergistically with chemotherapy by enhancing anti-tumor activity. ZOL blocks the mevalonate pathway and may indirectly interact with human epidermal growth factor receptor 2 (HER2) pathway activation. The clinical efficacy...
Na minha lista:
| Principais autores: | , , , , , , , , , , , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
SAGE Publishing
2019-05-01
|
| coleção: | Therapeutic Advances in Medical Oncology |
| Acesso em linha: | https://doi.org/10.1177/1758835919853971 |
| Tags: |
Sem tags, seja o primeiro a adicionar uma tag!
|